-
-
-
-
-
-
-
Outlook Therapeutics (OTLK) Reports Complete Twelve Week Efficacy and Safety Results of NORSE EIGHT Clinical Trial
-
-
-
-
-
-
-
Outlook Therapeutics (OTLK) Prices 28.46M Share Direct Offering at $0.88/sh
-
-
-
-
-
-
-
Form S-3 Outlook Therapeutics,
-
-
-
-
-
-
-
Outlook Therapeutics Announces $11.2 Million Financings Priced At-The-Market Under Nasdaq Rules
-
-
-
68,144 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

